- Home
- PK vs ZLAB Comparison
PK vs ZLAB Comparison
Compare PK & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PK | ZLAB |
|---|---|---|
| Founded | 1946 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | PK | ZLAB |
|---|---|---|
| Price | $10.66 | $19.02 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 6 |
| Target Price | $11.55 | ★ $57.22 |
| AVG Volume (30 Days) | ★ 3.5M | 832.3K |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | ★ 9.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,541,000,000.00 | $441,629,000.00 |
| Revenue This Year | N/A | $26.16 |
| Revenue Next Year | $2.07 | $30.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.14 |
| 52 Week Low | $8.27 | $16.82 |
| 52 Week High | $14.29 | $44.34 |
Technical Indicators
Market Signals| Indicator | PK | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 48.07 | 51.98 |
| Support Level | $10.36 | $17.18 |
| Resistance Level | $10.92 | $17.97 |
| Average True Range (ATR) | 0.26 | 0.61 |
| MACD | -0.02 | 0.33 |
| Stochastic Oscillator | 43.38 | 86.14 |
Price Performance
Historical ComparisonAbout PK Park Hotels & Resorts Inc.
Park Hotels & Resorts owns upper-upscale and luxury hotels, with 22,395 rooms across 36 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.